BioCryst Reports Second Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
JMP Securities Downgrades BioCryst Pharma (BCRX) to Market Perform
August 4, 2016 9:58 AM EDTJMP Securities downgraded BioCryst Pharma (NASDAQ: BCRX) from Market Outperform to Market Perform.
For an analyst ratings summary and ratings history on BioCryst Pharma click here. For more ratings news on BioCryst Pharma click here.
Shares of BioCryst Pharma closed at $4.03 yesterday.
... MoreBioCryst Pharma (BCRX) Tops Q2 EPS by 4c
August 4, 2016 8:35 AM EDTBioCryst Pharma (NASDAQ: BCRX) reported Q2 EPS of ($0.22), $0.04 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $4.8 million versus the consensus estimate of $3.92 million.
Cash, cash equivalents and investments decreased to $64.3 million at June 30, 2016, as compared to $100.9 million at... More
